Cargando…
Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model
Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has few...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Veterinary Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155206/ https://www.ncbi.nlm.nih.gov/pubmed/24849052 http://dx.doi.org/10.1292/jvms.14-0184 |
_version_ | 1782333562377207808 |
---|---|
author | ITAKURA, Masanori KOHDA, Tomoko KUBO, Takeya SEMI, Yuko NISHIYAMA, Kazuhiro AZUMA, Yasu-Taka NAKAJIMA, Hidemitsu KOZAKI, Shunji TAKEUCHI, Tadayoshi |
author_facet | ITAKURA, Masanori KOHDA, Tomoko KUBO, Takeya SEMI, Yuko NISHIYAMA, Kazuhiro AZUMA, Yasu-Taka NAKAJIMA, Hidemitsu KOZAKI, Shunji TAKEUCHI, Tadayoshi |
author_sort | ITAKURA, Masanori |
collection | PubMed |
description | Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson’s disease than BoNT/A1. |
format | Online Article Text |
id | pubmed-4155206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | The Japanese Society of Veterinary Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-41552062014-09-05 Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model ITAKURA, Masanori KOHDA, Tomoko KUBO, Takeya SEMI, Yuko NISHIYAMA, Kazuhiro AZUMA, Yasu-Taka NAKAJIMA, Hidemitsu KOZAKI, Shunji TAKEUCHI, Tadayoshi J Vet Med Sci Pharmacology Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson’s disease than BoNT/A1. The Japanese Society of Veterinary Science 2014-05-21 2014-08 /pmc/articles/PMC4155206/ /pubmed/24849052 http://dx.doi.org/10.1292/jvms.14-0184 Text en ©2014 The Japanese Society of Veterinary Science http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. |
spellingShingle | Pharmacology ITAKURA, Masanori KOHDA, Tomoko KUBO, Takeya SEMI, Yuko NISHIYAMA, Kazuhiro AZUMA, Yasu-Taka NAKAJIMA, Hidemitsu KOZAKI, Shunji TAKEUCHI, Tadayoshi Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model |
title | Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1
in a Rat Parkinson’s Disease Model |
title_full | Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1
in a Rat Parkinson’s Disease Model |
title_fullStr | Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1
in a Rat Parkinson’s Disease Model |
title_full_unstemmed | Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1
in a Rat Parkinson’s Disease Model |
title_short | Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1
in a Rat Parkinson’s Disease Model |
title_sort | botulinum neurotoxin type a subtype 2 confers greater safety than subtype 1
in a rat parkinson’s disease model |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155206/ https://www.ncbi.nlm.nih.gov/pubmed/24849052 http://dx.doi.org/10.1292/jvms.14-0184 |
work_keys_str_mv | AT itakuramasanori botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel AT kohdatomoko botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel AT kubotakeya botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel AT semiyuko botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel AT nishiyamakazuhiro botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel AT azumayasutaka botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel AT nakajimahidemitsu botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel AT kozakishunji botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel AT takeuchitadayoshi botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel |